Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Platelet Aggregation Inhibitors | 89 | 2022 | 2763 | 6.920 |
Why?
|
Ticlopidine | 56 | 2017 | 730 | 6.490 |
Why?
|
Thiophenes | 43 | 2015 | 569 | 5.770 |
Why?
|
Glucosides | 27 | 2024 | 533 | 5.530 |
Why?
|
Acute Coronary Syndrome | 69 | 2023 | 2192 | 4.840 |
Why?
|
Benzhydryl Compounds | 30 | 2024 | 940 | 4.780 |
Why?
|
Myocardial Infarction | 126 | 2024 | 11516 | 4.700 |
Why?
|
Piperazines | 42 | 2015 | 2552 | 3.680 |
Why?
|
Angioplasty, Balloon, Coronary | 38 | 2013 | 1724 | 3.160 |
Why?
|
Diabetes Mellitus, Type 2 | 49 | 2024 | 12241 | 3.130 |
Why?
|
Cardiovascular Diseases | 53 | 2024 | 15649 | 1.950 |
Why?
|
Anticholesteremic Agents | 21 | 2023 | 972 | 1.790 |
Why?
|
Platelet Activation | 9 | 2016 | 644 | 1.780 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 32 | 2024 | 3252 | 1.770 |
Why?
|
Heart Failure | 28 | 2024 | 11858 | 1.730 |
Why?
|
Thrombolytic Therapy | 22 | 2018 | 2050 | 1.710 |
Why?
|
Angina, Unstable | 16 | 2019 | 893 | 1.690 |
Why?
|
Pyridines | 27 | 2022 | 2889 | 1.540 |
Why?
|
Purinergic P2 Receptor Antagonists | 9 | 2011 | 67 | 1.480 |
Why?
|
Cholesterol, LDL | 20 | 2023 | 2398 | 1.340 |
Why?
|
Hemorrhage | 41 | 2025 | 3461 | 1.200 |
Why?
|
Platelet Function Tests | 6 | 2008 | 275 | 1.170 |
Why?
|
Blood Platelets | 11 | 2011 | 2476 | 1.110 |
Why?
|
Thrombosis | 19 | 2022 | 2955 | 1.090 |
Why?
|
Purinergic P2Y Receptor Antagonists | 14 | 2020 | 284 | 1.070 |
Why?
|
Registries | 31 | 2020 | 8379 | 1.060 |
Why?
|
Double-Blind Method | 63 | 2025 | 12456 | 1.060 |
Why?
|
Aspirin | 28 | 2020 | 3135 | 1.060 |
Why?
|
Cardiovascular System | 4 | 2023 | 838 | 1.030 |
Why?
|
Stroke | 36 | 2025 | 9742 | 1.020 |
Why?
|
Electrocardiography | 27 | 2018 | 6409 | 0.990 |
Why?
|
Treatment Outcome | 107 | 2024 | 65379 | 0.990 |
Why?
|
Drug Resistance | 8 | 2008 | 1595 | 0.950 |
Why?
|
Cardiovascular Agents | 2 | 2022 | 849 | 0.930 |
Why?
|
Imines | 3 | 2012 | 26 | 0.880 |
Why?
|
Drug Therapy, Combination | 35 | 2018 | 6318 | 0.840 |
Why?
|
Diabetic Cardiomyopathies | 3 | 2019 | 91 | 0.840 |
Why?
|
Fibrinolytic Agents | 14 | 2017 | 2074 | 0.830 |
Why?
|
Aged | 162 | 2025 | 171562 | 0.810 |
Why?
|
Stents | 14 | 2016 | 3201 | 0.750 |
Why?
|
Adenosine | 6 | 2016 | 817 | 0.750 |
Why?
|
Heptanoic Acids | 7 | 2011 | 344 | 0.750 |
Why?
|
Middle Aged | 169 | 2025 | 223491 | 0.750 |
Why?
|
Pravastatin | 7 | 2011 | 393 | 0.750 |
Why?
|
Simvastatin | 8 | 2017 | 346 | 0.750 |
Why?
|
Atrial Fibrillation | 11 | 2025 | 5168 | 0.720 |
Why?
|
Heparin | 11 | 2021 | 1636 | 0.710 |
Why?
|
Randomized Controlled Trials as Topic | 25 | 2024 | 10377 | 0.700 |
Why?
|
Anticoagulants | 19 | 2025 | 4843 | 0.700 |
Why?
|
Humans | 273 | 2025 | 768393 | 0.690 |
Why?
|
Glomerular Filtration Rate | 10 | 2024 | 2226 | 0.680 |
Why?
|
Benzazepines | 6 | 2019 | 311 | 0.670 |
Why?
|
Male | 190 | 2025 | 364902 | 0.660 |
Why?
|
Anti-Obesity Agents | 4 | 2024 | 240 | 0.640 |
Why?
|
Coronary Disease | 14 | 2017 | 5924 | 0.640 |
Why?
|
Hypercholesterolemia | 6 | 2022 | 1142 | 0.630 |
Why?
|
Female | 190 | 2025 | 397089 | 0.630 |
Why?
|
Hypoglycemic Agents | 14 | 2024 | 3108 | 0.600 |
Why?
|
Albuminuria | 2 | 2021 | 658 | 0.600 |
Why?
|
Coronary Artery Disease | 14 | 2021 | 6567 | 0.600 |
Why?
|
Receptors, Thrombin | 4 | 2014 | 130 | 0.600 |
Why?
|
Risk Assessment | 39 | 2024 | 24318 | 0.600 |
Why?
|
Symporters | 1 | 2020 | 363 | 0.590 |
Why?
|
Hirudins | 3 | 2017 | 179 | 0.580 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 11 | 2018 | 577 | 0.580 |
Why?
|
Diabetic Angiopathies | 4 | 2018 | 806 | 0.560 |
Why?
|
Acute Kidney Injury | 3 | 2022 | 1943 | 0.560 |
Why?
|
Creatinine | 3 | 2021 | 1915 | 0.560 |
Why?
|
Dose-Response Relationship, Drug | 26 | 2018 | 10776 | 0.560 |
Why?
|
Platelet Aggregation | 8 | 2011 | 769 | 0.550 |
Why?
|
Pyrroles | 7 | 2011 | 1126 | 0.550 |
Why?
|
Cholesterol, VLDL | 2 | 2024 | 70 | 0.550 |
Why?
|
Drug-Eluting Stents | 6 | 2016 | 681 | 0.550 |
Why?
|
Tyrosine | 7 | 2016 | 1428 | 0.540 |
Why?
|
Antithrombins | 2 | 2017 | 294 | 0.540 |
Why?
|
Coronary Angiography | 19 | 2020 | 4537 | 0.530 |
Why?
|
Obesity | 12 | 2024 | 13084 | 0.510 |
Why?
|
Patient Participation | 2 | 2015 | 1448 | 0.500 |
Why?
|
Hospitalization | 19 | 2023 | 10844 | 0.490 |
Why?
|
Brain Ischemia | 6 | 2020 | 3008 | 0.480 |
Why?
|
Coronary Thrombosis | 4 | 2014 | 440 | 0.480 |
Why?
|
Oxazolidinones | 3 | 2022 | 98 | 0.460 |
Why?
|
Renal Insufficiency, Chronic | 8 | 2024 | 2296 | 0.460 |
Why?
|
Risk Factors | 63 | 2024 | 74962 | 0.450 |
Why?
|
Thiazoles | 7 | 2022 | 1542 | 0.450 |
Why?
|
Cyclic N-Oxides | 5 | 2021 | 72 | 0.440 |
Why?
|
Antibodies, Monoclonal | 9 | 2022 | 9261 | 0.440 |
Why?
|
Atherosclerosis | 11 | 2023 | 3431 | 0.430 |
Why?
|
Peptide Fragments | 7 | 2024 | 5151 | 0.430 |
Why?
|
Diabetic Nephropathies | 4 | 2022 | 975 | 0.410 |
Why?
|
CD40 Ligand | 2 | 2012 | 524 | 0.410 |
Why?
|
Hypolipidemic Agents | 5 | 2018 | 609 | 0.400 |
Why?
|
Tissue Plasminogen Activator | 2 | 2017 | 1163 | 0.400 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2012 | 127 | 0.390 |
Why?
|
Time Factors | 40 | 2024 | 40272 | 0.390 |
Why?
|
Warfarin | 7 | 2022 | 1493 | 0.390 |
Why?
|
Natriuretic Peptide, Brain | 6 | 2024 | 1751 | 0.380 |
Why?
|
Thrombocytopenia | 2 | 2017 | 1180 | 0.370 |
Why?
|
Cause of Death | 12 | 2024 | 3728 | 0.370 |
Why?
|
Hospital Mortality | 12 | 2020 | 5367 | 0.360 |
Why?
|
Interleukin-18 | 1 | 2012 | 251 | 0.360 |
Why?
|
Follow-Up Studies | 35 | 2020 | 39407 | 0.360 |
Why?
|
Endpoint Determination | 6 | 2018 | 594 | 0.350 |
Why?
|
Overweight | 6 | 2024 | 2445 | 0.340 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7861 | 0.340 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 5 | 2010 | 246 | 0.340 |
Why?
|
Drug Administration Schedule | 14 | 2019 | 4859 | 0.340 |
Why?
|
Clinical Trials as Topic | 10 | 2019 | 8051 | 0.320 |
Why?
|
Myocardial Revascularization | 8 | 2018 | 796 | 0.320 |
Why?
|
Hyperlipidemias | 3 | 2023 | 773 | 0.310 |
Why?
|
Serotonin 5-HT2 Receptor Agonists | 2 | 2019 | 31 | 0.310 |
Why?
|
Chest Pain | 5 | 2015 | 1099 | 0.300 |
Why?
|
Kaplan-Meier Estimate | 15 | 2017 | 6541 | 0.300 |
Why?
|
Appetite Depressants | 2 | 2019 | 108 | 0.300 |
Why?
|
Enoxaparin | 5 | 2009 | 391 | 0.300 |
Why?
|
Quinolines | 2 | 2023 | 768 | 0.290 |
Why?
|
Myocardial Ischemia | 8 | 2018 | 2139 | 0.290 |
Why?
|
Death, Sudden, Cardiac | 8 | 2018 | 1568 | 0.290 |
Why?
|
Coronary Artery Bypass | 7 | 2018 | 2194 | 0.290 |
Why?
|
Lactones | 3 | 2014 | 316 | 0.280 |
Why?
|
Fluorobenzenes | 1 | 2009 | 179 | 0.280 |
Why?
|
Guideline Adherence | 9 | 2020 | 2240 | 0.280 |
Why?
|
Kidney Diseases | 5 | 2020 | 2103 | 0.280 |
Why?
|
Patient Discharge | 6 | 2021 | 3476 | 0.280 |
Why?
|
Cholesterol | 5 | 2024 | 2912 | 0.270 |
Why?
|
Lipoproteins, LDL | 3 | 2006 | 643 | 0.270 |
Why?
|
Stroke Volume | 3 | 2019 | 5619 | 0.260 |
Why?
|
Ventricular Function, Left | 1 | 2019 | 3941 | 0.260 |
Why?
|
Research Design | 7 | 2018 | 6210 | 0.250 |
Why?
|
Incidence | 21 | 2024 | 21544 | 0.250 |
Why?
|
Embolism | 2 | 2022 | 401 | 0.250 |
Why?
|
Proton Pump Inhibitors | 2 | 2013 | 553 | 0.250 |
Why?
|
Creatine Kinase, MB Form | 6 | 2014 | 202 | 0.240 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2020 | 876 | 0.240 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2006 | 169 | 0.240 |
Why?
|
Death | 2 | 2020 | 683 | 0.240 |
Why?
|
Triglycerides | 5 | 2024 | 2465 | 0.240 |
Why?
|
Insulin | 4 | 2023 | 6607 | 0.240 |
Why?
|
Health Status Disparities | 1 | 2016 | 1882 | 0.230 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 3 | 2019 | 317 | 0.230 |
Why?
|
Secondary Prevention | 13 | 2019 | 1476 | 0.230 |
Why?
|
Oligonucleotides, Antisense | 2 | 2024 | 461 | 0.230 |
Why?
|
Practice Guidelines as Topic | 16 | 2020 | 7453 | 0.230 |
Why?
|
Myocardial Reperfusion | 4 | 2014 | 339 | 0.230 |
Why?
|
Pulmonary Embolism | 1 | 2017 | 2587 | 0.220 |
Why?
|
Multicenter Studies as Topic | 5 | 2018 | 1727 | 0.220 |
Why?
|
Weight Loss | 5 | 2024 | 2713 | 0.220 |
Why?
|
Aged, 80 and over | 27 | 2025 | 59686 | 0.220 |
Why?
|
Glucose | 5 | 2022 | 4352 | 0.220 |
Why?
|
Administration, Oral | 5 | 2025 | 4039 | 0.210 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 155 | 0.210 |
Why?
|
Recurrence | 12 | 2021 | 8506 | 0.210 |
Why?
|
Troponin | 3 | 2020 | 534 | 0.200 |
Why?
|
Hyperglycemia | 1 | 2011 | 1389 | 0.200 |
Why?
|
C-Reactive Protein | 8 | 2016 | 3857 | 0.200 |
Why?
|
Drug Monitoring | 2 | 2018 | 964 | 0.190 |
Why?
|
Coronary Stenosis | 3 | 2014 | 802 | 0.190 |
Why?
|
Blood Coagulation | 2 | 2018 | 1161 | 0.190 |
Why?
|
Sodium | 3 | 2022 | 1594 | 0.190 |
Why?
|
Receptor, PAR-1 | 2 | 2012 | 109 | 0.190 |
Why?
|
Blood Glucose | 2 | 2017 | 6430 | 0.190 |
Why?
|
No-Reflow Phenomenon | 1 | 2021 | 16 | 0.190 |
Why?
|
Heart | 1 | 2014 | 4449 | 0.190 |
Why?
|
Hypokalemia | 1 | 2022 | 153 | 0.180 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 70 | 0.180 |
Why?
|
Peripheral Arterial Disease | 3 | 2022 | 1303 | 0.180 |
Why?
|
Ventricular Function | 4 | 2006 | 406 | 0.180 |
Why?
|
Combined Modality Therapy | 8 | 2014 | 8562 | 0.180 |
Why?
|
Healthcare Disparities | 1 | 2016 | 3413 | 0.180 |
Why?
|
Eye Hemorrhage | 1 | 2020 | 19 | 0.170 |
Why?
|
Acute Disease | 9 | 2014 | 7242 | 0.170 |
Why?
|
Primary Prevention | 3 | 2021 | 1187 | 0.170 |
Why?
|
Sex Characteristics | 3 | 2021 | 2660 | 0.170 |
Why?
|
Hyperkalemia | 1 | 2022 | 233 | 0.170 |
Why?
|
Diuretics | 1 | 2022 | 612 | 0.160 |
Why?
|
Sulfonamides | 1 | 2009 | 1980 | 0.160 |
Why?
|
Morpholines | 2 | 2013 | 584 | 0.160 |
Why?
|
United States | 27 | 2020 | 73150 | 0.160 |
Why?
|
Models, Biological | 2 | 2012 | 9493 | 0.150 |
Why?
|
Whole Blood Coagulation Time | 1 | 2018 | 30 | 0.150 |
Why?
|
Appetite Regulation | 1 | 2019 | 84 | 0.150 |
Why?
|
Hospitals | 3 | 2020 | 3906 | 0.150 |
Why?
|
Life Expectancy | 2 | 2024 | 1249 | 0.150 |
Why?
|
Prodrugs | 3 | 2009 | 275 | 0.150 |
Why?
|
Diuresis | 1 | 2018 | 106 | 0.150 |
Why?
|
Drug Therapy | 1 | 2021 | 504 | 0.150 |
Why?
|
Risk | 10 | 2020 | 9636 | 0.150 |
Why?
|
Decision Support Techniques | 2 | 2019 | 2006 | 0.150 |
Why?
|
Syndrome | 5 | 2008 | 3275 | 0.140 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2022 | 1066 | 0.140 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1735 | 0.140 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2018 | 174 | 0.140 |
Why?
|
Adamantane | 2 | 2019 | 148 | 0.140 |
Why?
|
Cholesterol, HDL | 6 | 2022 | 1820 | 0.140 |
Why?
|
Severity of Illness Index | 9 | 2020 | 15939 | 0.140 |
Why?
|
Pyrimidines | 1 | 2009 | 3048 | 0.140 |
Why?
|
Infusions, Intravenous | 3 | 2017 | 2226 | 0.140 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2017 | 113 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 6 | 2017 | 20765 | 0.130 |
Why?
|
Hypoglycemia | 3 | 2019 | 894 | 0.130 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 399 | 0.130 |
Why?
|
Aryldialkylphosphatase | 1 | 2016 | 64 | 0.130 |
Why?
|
Dipeptides | 2 | 2019 | 386 | 0.130 |
Why?
|
Peptides | 4 | 2016 | 4353 | 0.130 |
Why?
|
Angioplasty | 2 | 2011 | 357 | 0.130 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1517 | 0.130 |
Why?
|
Kidney | 5 | 2023 | 7064 | 0.120 |
Why?
|
Extremities | 1 | 2020 | 870 | 0.120 |
Why?
|
Proportional Hazards Models | 10 | 2019 | 12558 | 0.120 |
Why?
|
Drug Substitution | 1 | 2017 | 291 | 0.120 |
Why?
|
Phentermine | 1 | 2014 | 31 | 0.120 |
Why?
|
Postoperative Complications | 4 | 2018 | 15881 | 0.120 |
Why?
|
Benzaldehydes | 1 | 2014 | 59 | 0.120 |
Why?
|
Cyclopropanes | 1 | 2016 | 437 | 0.120 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 1026 | 0.120 |
Why?
|
Recombinant Proteins | 5 | 2017 | 6510 | 0.120 |
Why?
|
Azetidines | 1 | 2015 | 143 | 0.110 |
Why?
|
Patient Selection | 4 | 2019 | 4266 | 0.110 |
Why?
|
Survival Analysis | 8 | 2019 | 10117 | 0.110 |
Why?
|
Adult | 29 | 2024 | 223640 | 0.110 |
Why?
|
Logistic Models | 8 | 2013 | 13323 | 0.110 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2008 | 3440 | 0.110 |
Why?
|
Prospective Studies | 8 | 2020 | 54920 | 0.110 |
Why?
|
Risk Reduction Behavior | 2 | 2019 | 1118 | 0.110 |
Why?
|
Angina Pectoris | 3 | 2007 | 960 | 0.110 |
Why?
|
Prevalence | 6 | 2021 | 15872 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2019 | 809 | 0.110 |
Why?
|
Multivariate Analysis | 5 | 2017 | 12092 | 0.110 |
Why?
|
Sex Factors | 5 | 2021 | 10654 | 0.110 |
Why?
|
Disease Progression | 6 | 2023 | 13646 | 0.110 |
Why?
|
Fibrinolysis | 2 | 2011 | 331 | 0.110 |
Why?
|
Predictive Value of Tests | 9 | 2019 | 15455 | 0.110 |
Why?
|
Oximes | 1 | 2014 | 303 | 0.100 |
Why?
|
Cerebral Infarction | 1 | 2018 | 975 | 0.100 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 692 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2017 | 1837 | 0.100 |
Why?
|
Venous Thrombosis | 1 | 2022 | 1317 | 0.100 |
Why?
|
Acetanilides | 1 | 2014 | 169 | 0.100 |
Why?
|
Bupropion | 1 | 2014 | 304 | 0.100 |
Why?
|
Fructose | 1 | 2014 | 284 | 0.100 |
Why?
|
Receptors, Purinergic P2Y12 | 3 | 2011 | 117 | 0.100 |
Why?
|
Troponin I | 2 | 2012 | 662 | 0.100 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 797 | 0.100 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2016 | 340 | 0.100 |
Why?
|
Troponin T | 2 | 2015 | 787 | 0.100 |
Why?
|
Naltrexone | 1 | 2014 | 319 | 0.100 |
Why?
|
Uncertainty | 1 | 2016 | 759 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2017 | 904 | 0.100 |
Why?
|
Myocarditis | 1 | 2019 | 803 | 0.090 |
Why?
|
Meta-Analysis as Topic | 2 | 2006 | 1364 | 0.090 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 2016 | 446 | 0.090 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2034 | 0.090 |
Why?
|
Intraoperative Care | 1 | 2015 | 771 | 0.090 |
Why?
|
Protein Precursors | 2 | 2013 | 1134 | 0.090 |
Why?
|
Diabetes Mellitus | 4 | 2017 | 5891 | 0.090 |
Why?
|
Polymorphism, Genetic | 3 | 2010 | 4250 | 0.090 |
Why?
|
Injections, Subcutaneous | 2 | 2025 | 687 | 0.090 |
Why?
|
Eligibility Determination | 1 | 2014 | 421 | 0.090 |
Why?
|
Chi-Square Distribution | 6 | 2012 | 3438 | 0.090 |
Why?
|
Anemia | 1 | 2020 | 1519 | 0.090 |
Why?
|
Evidence-Based Medicine | 3 | 2014 | 3707 | 0.090 |
Why?
|
Inpatients | 2 | 2012 | 2570 | 0.090 |
Why?
|
Cross-Over Studies | 4 | 2011 | 2106 | 0.090 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 692 | 0.090 |
Why?
|
Transportation of Patients | 1 | 2011 | 176 | 0.090 |
Why?
|
Platelet Adhesiveness | 1 | 2010 | 154 | 0.090 |
Why?
|
Metformin | 1 | 2018 | 911 | 0.090 |
Why?
|
International Normalized Ratio | 1 | 2012 | 382 | 0.090 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2019 | 1398 | 0.080 |
Why?
|
Emergency Service, Hospital | 4 | 2013 | 7955 | 0.080 |
Why?
|
Early Diagnosis | 1 | 2015 | 1195 | 0.080 |
Why?
|
Streptokinase | 1 | 2009 | 186 | 0.080 |
Why?
|
Italy | 1 | 2011 | 854 | 0.080 |
Why?
|
Blood Proteins | 1 | 2014 | 1186 | 0.080 |
Why?
|
Blood Pressure | 2 | 2022 | 8541 | 0.080 |
Why?
|
Drug Interactions | 2 | 2013 | 1420 | 0.080 |
Why?
|
Health Services Research | 1 | 2016 | 1817 | 0.080 |
Why?
|
Reproducibility of Results | 7 | 2019 | 20224 | 0.080 |
Why?
|
Data Collection | 1 | 2018 | 3324 | 0.080 |
Why?
|
Prognosis | 12 | 2024 | 30022 | 0.080 |
Why?
|
Odds Ratio | 8 | 2013 | 9682 | 0.080 |
Why?
|
Lipoproteins | 2 | 2024 | 880 | 0.080 |
Why?
|
Cohort Studies | 9 | 2018 | 41795 | 0.080 |
Why?
|
Membrane Proteins | 1 | 2005 | 7880 | 0.080 |
Why?
|
Body Mass Index | 3 | 2024 | 13052 | 0.080 |
Why?
|
Drug Combinations | 1 | 2014 | 2079 | 0.080 |
Why?
|
Apolipoproteins B | 2 | 2022 | 386 | 0.080 |
Why?
|
Genotype | 6 | 2016 | 13042 | 0.070 |
Why?
|
Coronary Circulation | 3 | 2014 | 1617 | 0.070 |
Why?
|
Cardiology | 1 | 2019 | 1701 | 0.070 |
Why?
|
Liver | 1 | 2023 | 7574 | 0.070 |
Why?
|
Myocardial Contraction | 3 | 1999 | 1527 | 0.070 |
Why?
|
Nitric Oxide Synthase | 4 | 1999 | 911 | 0.070 |
Why?
|
Intracranial Hemorrhages | 5 | 2015 | 811 | 0.070 |
Why?
|
Diagnostic Tests, Routine | 1 | 2013 | 790 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2349 | 0.070 |
Why?
|
Niacin | 2 | 2019 | 117 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2016 | 2593 | 0.070 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2009 | 423 | 0.070 |
Why?
|
Fibrin | 1 | 2009 | 514 | 0.070 |
Why?
|
Helminth Proteins | 1 | 2007 | 172 | 0.070 |
Why?
|
Survival Rate | 7 | 2018 | 12870 | 0.070 |
Why?
|
Drug Prescriptions | 1 | 2015 | 1673 | 0.070 |
Why?
|
Drug Dosage Calculations | 2 | 2018 | 117 | 0.060 |
Why?
|
Awareness | 1 | 2010 | 653 | 0.060 |
Why?
|
Life Tables | 1 | 2006 | 368 | 0.060 |
Why?
|
Adenosine Monophosphate | 1 | 2007 | 233 | 0.060 |
Why?
|
Adiponectin | 1 | 2011 | 1117 | 0.060 |
Why?
|
Chemokine CCL2 | 1 | 2007 | 606 | 0.060 |
Why?
|
Triage | 1 | 2012 | 994 | 0.060 |
Why?
|
Factor XI | 1 | 2025 | 40 | 0.060 |
Why?
|
Sex Distribution | 3 | 2017 | 2281 | 0.060 |
Why?
|
Thromboxane A2 | 1 | 2004 | 87 | 0.060 |
Why?
|
Exercise Test | 2 | 2011 | 2186 | 0.060 |
Why?
|
Circadian Rhythm | 2 | 2013 | 2588 | 0.060 |
Why?
|
Enzyme Inhibitors | 2 | 2014 | 3722 | 0.060 |
Why?
|
Antifibrinolytic Agents | 1 | 2007 | 289 | 0.060 |
Why?
|
Case Management | 1 | 2006 | 276 | 0.060 |
Why?
|
Angiopoietins | 1 | 2024 | 86 | 0.060 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2006 | 361 | 0.060 |
Why?
|
Microfilament Proteins | 1 | 2009 | 1135 | 0.060 |
Why?
|
Retrospective Studies | 15 | 2014 | 81801 | 0.060 |
Why?
|
Algorithms | 3 | 2020 | 14154 | 0.050 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2862 | 0.050 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 89 | 0.050 |
Why?
|
Plaque, Atherosclerotic | 1 | 2014 | 1548 | 0.050 |
Why?
|
Cell Adhesion Molecules | 1 | 2009 | 1614 | 0.050 |
Why?
|
Subtilisins | 1 | 2022 | 79 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1813 | 0.050 |
Why?
|
Creatine Kinase | 1 | 2004 | 685 | 0.050 |
Why?
|
China | 2 | 2020 | 2395 | 0.050 |
Why?
|
Length of Stay | 2 | 2012 | 6519 | 0.050 |
Why?
|
Neoplasms | 4 | 2019 | 22385 | 0.050 |
Why?
|
Isoenzymes | 2 | 2004 | 1684 | 0.050 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2023 | 199 | 0.050 |
Why?
|
Aging | 1 | 2019 | 8764 | 0.040 |
Why?
|
Women's Health | 1 | 2010 | 2078 | 0.040 |
Why?
|
Phenylbutazone | 1 | 2020 | 7 | 0.040 |
Why?
|
Tolbutamide | 1 | 2020 | 23 | 0.040 |
Why?
|
Hematocrit | 1 | 2022 | 625 | 0.040 |
Why?
|
United States Food and Drug Administration | 2 | 2020 | 1672 | 0.040 |
Why?
|
Phosphoproteins | 1 | 2009 | 2448 | 0.040 |
Why?
|
Coronary Vessels | 1 | 2011 | 3125 | 0.040 |
Why?
|
Necrosis | 1 | 2004 | 1621 | 0.040 |
Why?
|
Equipment Design | 1 | 2008 | 3529 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5708 | 0.040 |
Why?
|
Age Distribution | 2 | 2017 | 2877 | 0.040 |
Why?
|
Europe | 1 | 2006 | 3439 | 0.040 |
Why?
|
Adenosine Diphosphate | 2 | 2011 | 422 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2024 | 14784 | 0.040 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2000 | 881 | 0.040 |
Why?
|
Inflammation | 2 | 2012 | 10863 | 0.040 |
Why?
|
Nitric Oxide | 2 | 1999 | 2144 | 0.040 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2016 | 1244 | 0.040 |
Why?
|
Up-Regulation | 3 | 2016 | 4142 | 0.040 |
Why?
|
Oxazoles | 1 | 2020 | 199 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2009 | 5538 | 0.040 |
Why?
|
Comorbidity | 3 | 2011 | 10588 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 2708 | 0.040 |
Why?
|
Smoking | 2 | 2013 | 9111 | 0.040 |
Why?
|
Lipids | 2 | 2006 | 3344 | 0.040 |
Why?
|
Potassium | 1 | 2022 | 1318 | 0.040 |
Why?
|
Carbazoles | 1 | 1999 | 221 | 0.040 |
Why?
|
Nitroso Compounds | 1 | 1997 | 71 | 0.030 |
Why?
|
Down-Regulation | 1 | 2024 | 2940 | 0.030 |
Why?
|
DNA | 1 | 2010 | 7211 | 0.030 |
Why?
|
Digitalis Glycosides | 1 | 2016 | 47 | 0.030 |
Why?
|
Vascular Patency | 2 | 2010 | 916 | 0.030 |
Why?
|
HIV Infections | 1 | 2023 | 17575 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2017 | 368 | 0.030 |
Why?
|
Glycine | 1 | 2020 | 672 | 0.030 |
Why?
|
Pharmacogenetics | 2 | 2010 | 683 | 0.030 |
Why?
|
Diabetic Ketoacidosis | 1 | 2019 | 255 | 0.030 |
Why?
|
Rhabdomyolysis | 1 | 2017 | 152 | 0.030 |
Why?
|
Liver Diseases | 2 | 2017 | 1304 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 417 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2017 | 305 | 0.030 |
Why?
|
Long QT Syndrome | 1 | 2000 | 472 | 0.030 |
Why?
|
Disease Management | 2 | 2017 | 2537 | 0.030 |
Why?
|
Government Regulation | 1 | 2020 | 525 | 0.030 |
Why?
|
Sulfhydryl Compounds | 1 | 1997 | 296 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2019 | 487 | 0.030 |
Why?
|
Drug Utilization | 2 | 2012 | 1191 | 0.030 |
Why?
|
Genetic Variation | 1 | 2010 | 6606 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 417 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2017 | 640 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 18048 | 0.030 |
Why?
|
Norepinephrine | 1 | 1997 | 900 | 0.030 |
Why?
|
Injections, Intravenous | 2 | 2013 | 1379 | 0.030 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 13020 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 577 | 0.030 |
Why?
|
Receptors, LDL | 1 | 2016 | 491 | 0.030 |
Why?
|
Age Factors | 3 | 2019 | 18471 | 0.030 |
Why?
|
Body Weight | 2 | 2018 | 4629 | 0.030 |
Why?
|
Area Under Curve | 2 | 2008 | 1642 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2020 | 1309 | 0.030 |
Why?
|
Placebo Effect | 1 | 2017 | 518 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 806 | 0.030 |
Why?
|
Cardiotonic Agents | 1 | 2016 | 544 | 0.030 |
Why?
|
Drug Utilization Review | 1 | 2014 | 248 | 0.030 |
Why?
|
Myocardium | 2 | 2004 | 4788 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2019 | 712 | 0.030 |
Why?
|
Graft Occlusion, Vascular | 1 | 2016 | 538 | 0.030 |
Why?
|
Muscular Diseases | 1 | 2017 | 554 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 548 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8731 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 2407 | 0.030 |
Why?
|
Pyridostigmine Bromide | 1 | 1992 | 32 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2027 | 0.030 |
Why?
|
Lipoprotein(a) | 1 | 2017 | 490 | 0.030 |
Why?
|
Internationality | 1 | 2017 | 1008 | 0.020 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2011 | 68 | 0.020 |
Why?
|
Regression Analysis | 2 | 2012 | 6350 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2016 | 1742 | 0.020 |
Why?
|
Long-Term Care | 1 | 2015 | 632 | 0.020 |
Why?
|
Platelet Activating Factor | 1 | 2011 | 143 | 0.020 |
Why?
|
Tachycardia, Ventricular | 1 | 2000 | 1309 | 0.020 |
Why?
|
Hip Fractures | 1 | 2019 | 996 | 0.020 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2016 | 856 | 0.020 |
Why?
|
Indoles | 1 | 1999 | 1825 | 0.020 |
Why?
|
Databases, Factual | 2 | 2021 | 8075 | 0.020 |
Why?
|
Reperfusion | 1 | 2011 | 266 | 0.020 |
Why?
|
Retreatment | 1 | 2012 | 600 | 0.020 |
Why?
|
Preventive Health Services | 1 | 2015 | 568 | 0.020 |
Why?
|
Somatostatin | 1 | 1992 | 458 | 0.020 |
Why?
|
Treatment Failure | 1 | 2016 | 2663 | 0.020 |
Why?
|
Growth Hormone | 1 | 1992 | 573 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2019 | 2006 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2755 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2011 | 715 | 0.020 |
Why?
|
Biotransformation | 1 | 2009 | 166 | 0.020 |
Why?
|
Microsomes, Liver | 1 | 2009 | 174 | 0.020 |
Why?
|
Plasminogen Activators | 1 | 2009 | 199 | 0.020 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2010 | 344 | 0.020 |
Why?
|
Calcium | 2 | 1999 | 5794 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2623 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1397 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2000 | 9562 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2018 | 1597 | 0.020 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2018 | 1568 | 0.020 |
Why?
|
Shock, Cardiogenic | 1 | 2013 | 711 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2019 | 2062 | 0.020 |
Why?
|
Enzyme Activation | 3 | 1999 | 3587 | 0.020 |
Why?
|
ROC Curve | 1 | 2015 | 3623 | 0.020 |
Why?
|
American Heart Association | 1 | 2011 | 1051 | 0.020 |
Why?
|
Adolescent | 4 | 2012 | 89184 | 0.020 |
Why?
|
Research | 1 | 2015 | 1981 | 0.020 |
Why?
|
Bone Density | 1 | 2019 | 3559 | 0.020 |
Why?
|
Pancreatitis | 1 | 2013 | 1087 | 0.020 |
Why?
|
Health Status | 1 | 2019 | 4094 | 0.020 |
Why?
|
Health Resources | 1 | 2012 | 950 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1962 | 0.020 |
Why?
|
Medication Adherence | 1 | 2017 | 2189 | 0.020 |
Why?
|
Pyrrolidines | 1 | 2007 | 340 | 0.020 |
Why?
|
Echocardiography | 1 | 2018 | 5044 | 0.020 |
Why?
|
Electrophysiology | 2 | 2000 | 1266 | 0.020 |
Why?
|
Home Care Services | 1 | 2012 | 659 | 0.020 |
Why?
|
International Cooperation | 1 | 2011 | 1438 | 0.020 |
Why?
|
Alanine | 1 | 2007 | 613 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 890 | 0.010 |
Why?
|
Heart Rate | 1 | 2016 | 4218 | 0.010 |
Why?
|
Probability | 1 | 2010 | 2482 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2010 | 2931 | 0.010 |
Why?
|
Phosphorylation | 2 | 2009 | 8326 | 0.010 |
Why?
|
Immunotherapy | 1 | 2019 | 4738 | 0.010 |
Why?
|
Seasons | 1 | 2009 | 1526 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5375 | 0.010 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2013 | 2144 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 3 | 1999 | 8199 | 0.010 |
Why?
|
Heterozygote | 1 | 2008 | 2791 | 0.010 |
Why?
|
Decision Making | 1 | 2015 | 3953 | 0.010 |
Why?
|
Postoperative Care | 1 | 2008 | 1480 | 0.010 |
Why?
|
Drug Costs | 1 | 2009 | 1196 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 13503 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2011 | 2337 | 0.010 |
Why?
|
Gemfibrozil | 1 | 2000 | 30 | 0.010 |
Why?
|
Rats | 4 | 1999 | 23835 | 0.010 |
Why?
|
Quality Improvement | 1 | 2015 | 3858 | 0.010 |
Why?
|
Young Adult | 3 | 2012 | 60049 | 0.010 |
Why?
|
Nitroarginine | 1 | 1999 | 66 | 0.010 |
Why?
|
Cyclic GMP-Dependent Protein Kinases | 1 | 1999 | 28 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26375 | 0.010 |
Why?
|
Linear Models | 1 | 2009 | 5878 | 0.010 |
Why?
|
Health Care Costs | 1 | 2012 | 3267 | 0.010 |
Why?
|
Methylene Blue | 1 | 1999 | 156 | 0.010 |
Why?
|
Tunica Intima | 1 | 2000 | 459 | 0.010 |
Why?
|
Alkaloids | 1 | 1999 | 192 | 0.010 |
Why?
|
Cyclic GMP | 1 | 1999 | 394 | 0.010 |
Why?
|
Arrhythmias, Cardiac | 1 | 2007 | 2258 | 0.010 |
Why?
|
S-Nitroso-N-Acetylpenicillamine | 1 | 1997 | 23 | 0.010 |
Why?
|
Neurons | 1 | 1997 | 9513 | 0.010 |
Why?
|
Homocysteine | 1 | 2000 | 637 | 0.010 |
Why?
|
Penicillamine | 1 | 1997 | 60 | 0.010 |
Why?
|
Ganglia, Sympathetic | 1 | 1997 | 65 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2009 | 1946 | 0.010 |
Why?
|
Cell Size | 1 | 1999 | 626 | 0.010 |
Why?
|
PC12 Cells | 1 | 1997 | 317 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 2000 | 1376 | 0.010 |
Why?
|
Electroencephalography | 1 | 2012 | 6317 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2012 | 14737 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9379 | 0.010 |
Why?
|
Enzyme Induction | 1 | 1996 | 455 | 0.010 |
Why?
|
Carotid Arteries | 1 | 2000 | 943 | 0.010 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 1999 | 706 | 0.010 |
Why?
|
Reaction Time | 1 | 2000 | 2103 | 0.010 |
Why?
|
Hormones | 1 | 1997 | 870 | 0.010 |
Why?
|
Coculture Techniques | 1 | 1997 | 1342 | 0.010 |
Why?
|
Reference Values | 1 | 2000 | 4941 | 0.010 |
Why?
|
Action Potentials | 1 | 2000 | 1838 | 0.010 |
Why?
|
Biological Transport | 1 | 1997 | 2085 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1992 | 862 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 16028 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 1992 | 2087 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 1997 | 2225 | 0.010 |
Why?
|
Animals | 6 | 2000 | 169337 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1997 | 19022 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2007 | 22296 | 0.010 |
Why?
|
Heart Ventricles | 1 | 1999 | 3838 | 0.000 |
Why?
|
Endothelium, Vascular | 1 | 1996 | 4427 | 0.000 |
Why?
|
Mutation | 1 | 2008 | 30228 | 0.000 |
Why?
|
Phenotype | 1 | 2000 | 16721 | 0.000 |
Why?
|
Cytokines | 1 | 1996 | 7445 | 0.000 |
Why?
|
Mice | 1 | 2000 | 82017 | 0.000 |
Why?
|